Table of Contents
Chemotherapy Research and Practice
Volume 2011 (2011), Article ID 878912, 8 pages
http://dx.doi.org/10.1155/2011/878912
Review Article

New Agents Targeting Angiogenesis in Glioblastoma

Department of Medical Oncology, Aristotle University of Thessaloniki School of Medicine and General Hospital “Papageorgiou”, 54303 Thessaloniki, Greece

Received 30 April 2011; Revised 22 July 2011; Accepted 23 August 2011

Academic Editor: Andreas F. Hottinger

Copyright © 2011 Eleni Timotheadou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Glioblastoma is the most common malignant glioma in adults, and despite recent advances in standard treatment, the prognosis still remains dismal, with a median survival of 15 months. The incorporation of bevacizumab in the standard treatment of relapsed glioblastoma has been a significant step towards combining targeted agents with chemotherapy, and there is an increasing number of new antiangiogenic agents in various stages of development, that are being tested both in relapsed and newly diagnosed disease, alone or in combination with standard treatment. The relatively favorable toxicity profile for most of them presents an advantage, but several concerns arise regarding their actual efficacy on the clinical level and the most efficient schedule of administration for each of them, as their molecular targets and patterns of action may vary significantly. This may lead to future modifications of the current rational of administering these agents concomitantly with initial chemotherapy or maintenance treatment.